Archive: Company News
Company News: Project Group ProDetekt at Life Science Inkubator (LSI) Sachsen receives maximum patent protection in Europe for PRET-ELISA key technology
– Significant performance and efficiency improvement of ELISA-based protein analytics
Dresden, Germany, March 15, 2018 – ProDetekt, a start-up project incubated at Life Science Inkubator Sachsen, has been granted broad European patent protection for its novel PRET-ELISA technology supplementing the ELISA method used in bioanalytics world-wide. ELISA (Enzyme-linked Immunosorbent Assay) is being applied routinely in biomedical research and everyday clinical practice, e.g. to determine disease-relevant biomarkers in complex biological samples.
— IP position strengthened in the U.S.
— Patent supports utility of Unyvero Lysator Technology for sample preparation
Curetis N.V. (the “Company” and, together with Curetis USA Inc. and Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that it has received a notice of allowance from the United States Patent & Trademark Office (USPTO) for U.S. Patent Application 14/232,391 (“Apparatus and Method for a Lysis of a Sample, in Particular for an Automated and/or Controlled Lysis of a Sample”) covering its Unyvero Lysator patient sample preparation technology.
— Award winner in “GoSiliconValley” competition by Austrian Economic Chambers
— Support for business development in U.S. market
Curetis N.V. (the “Company” and, together with Curetis USA Inc. and Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that its wholly-owned subsidiary Ares Genetics GmbH (Vienna, Austria) has been selected as a winner of the “GoSiliconValley” competition of the Austrian Economic Chambers (WKO).
Company News: ISA Pharmaceuticals and Scancell enter collaboration agreement for the manufacturing, development and commercialisation of Modi-1 / AMPLIVANT® combination
— AMPLIVANT-Modi-1 conjugate expected to enter clinic in H1 2019
— Collaboration seeks to further leverage Moditope® platform
ISA Pharmaceuticals B.V. (‘ISA’), a clinical-stage immunotherapy company, and Scancell Holdings plc, (‘Scancell’ or the ‘Company’), the developer of novel immunotherapies for the treatment of cancer, are pleased to announce that they have entered into a worldwide licensing and collaboration agreement to use ISA’s AMPLIVANT® adjuvant technology for the manufacturing, development and commercialisation of Scancell’s first Moditope® development candidate, Modi-1.